Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-10 06:10 am Sale | 13D | PHATHOM PHARMACEUTICALS INC CO PHAT | TAKEDA PHARMACEUTICAL CO LTD TAK | 2,790,480 4.8% | -362,737 (-11.50%) | View |
| 2024-04-01 06:15 am Sale | 13D | PHATHOM PHARMACEUTICALS INC CO PHAT | TAKEDA PHARMACEUTICAL CO LTD TAK | 3,153,217 5.4% | -602,366 (-16.04%) | View |
| 2024-02-12 4:36 pm Purchase | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Carlyle Group Inc. CG | 3,496,808 6.1% | 561,702 (+19.14%) | View |
| 2024-02-09 11:45 am Purchase | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Invesco Ltd. IVZ | 3,167,653 5.5% | 960,004 (+43.49%) | View |
| 2024-01-26 4:00 pm Purchase | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Medicxi Growth I LP | 7,464,572 13% | 4,980,298 (+200.47%) | View |
| 2024-01-25 06:11 am Sale | 13D | PHATHOM PHARMACEUTICALS INC CO PHAT | TAKEDA PHARMACEUTICAL CO LTD TAK | 3,755,583 6.6% | -3,703,721 (-49.65%) | View |
| 2023-05-26 5:29 pm Purchase | 13D | PHATHOM PHARMACEUTICALS INC CO PHAT | Frazier Life Sciences Public Fund L.P. | 10,125,788 18.5% | 1,697,683 (+20.14%) | View |
| 2023-05-05 4:13 pm Purchase | 13D | PHATHOM PHARMACEUTICALS INC CO PHAT | Frazier Life Sciences Public Fund L.P. | 8,428,105 19.3% | 8,428,105 (New Position) | View |
| 2023-03-09 4:17 pm Purchase | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Carlyle Group Inc. CG | 2,935,106 6.7% | 2,935,106 (New Position) | View |
| 2023-02-14 1:58 pm Purchase | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Avidity Partners Management LP | 1,900,000 4.6% | 4,000 (+0.21%) | View |
| 2023-02-10 3:59 pm Sale | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Flynn James E | 0 0% | -2,414,897 (Position Closed) | View |
| 2023-02-09 11:30 am Sale | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | VANGUARD GROUP INC | 1,076,605 2.59% | -851,239 (-44.15%) | View |
| 2023-02-09 11:18 am Sale | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | JANUS HENDERSON GROUP PLC JHG | 2,952 0% | -1,838,405 (-99.84%) | View |
| 2023-02-02 3:08 pm Purchase | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Invesco Ltd. IVZ | 2,207,649 5.3% | 140,293 (+6.79%) | View |
| 2023-01-31 4:00 pm Purchase | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Medicxi Growth I LP | 2,484,274 6% | 416,413 (+20.14%) | View |
| 2022-09-26 4:00 pm Purchase | 13D | PHATHOM PHARMACEUTICALS INC CO PHAT | Frazier Life Sciences IX L.P. | 8,424,772 21.5% | 203,448 (+2.47%) | View |
| 2022-09-23 5:15 pm Purchase | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | Flynn James E | 2,414,897 5.81% | 2,414,897 (New Position) | View |
| 2022-08-11 3:55 pm Purchase | 13D | PHATHOM PHARMACEUTICALS INC CO PHAT | Frazier Life Sciences IX L.P. | 8,221,324 21% | 2,377,400 (+40.68%) | View |
| 2022-05-16 4:32 pm Sale | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | RA CAPITAL MANAGEMENT L.P. | 0 0% | -3,115,008 (Position Closed) | View |
| 2022-02-14 4:11 pm Sale | 13G | PHATHOM PHARMACEUTICALS INC CO PHAT | RA CAPITAL MANAGEMENT L.P. | 3,115,008 9.9% | -710,000 (-18.56%) | View |